PHARMACEUTICAL PRODUCT DEVELOPMENT INC Net Income
PHARMACEUTICAL PRODUCT DEVELOPMENT INC reported Net Income of $35.62 million for the 3-month period ending 2011-09-30, per its 10-Q filed 2011-11-02.
Discontinued › Income Statement › Net Income
us-gaap:NetIncomeLoss · last filed 2011-11-02
- PHARMACEUTICAL PRODUCT DEVELOPMENT INC net income (loss) attributable to parent for the quarter ending 2011-09-30 was $35.62M, a 6.28% decline year-over-year.
- PHARMACEUTICAL PRODUCT DEVELOPMENT INC net income (loss) attributable to parent for the quarter ending 2011-06-30 was $45.41M, a 116.50% increase year-over-year.
- PHARMACEUTICAL PRODUCT DEVELOPMENT INC net income (loss) attributable to parent for the quarter ending 2011-03-31 was $37.37M, a 117.19% increase year-over-year.
- PHARMACEUTICAL PRODUCT DEVELOPMENT INC net income (loss) attributable to parent for the quarter ending 2010-12-31 was $47.48M, a 150.02% increase year-over-year.
- PHARMACEUTICAL PRODUCT DEVELOPMENT INC net income (loss) attributable to parent for fiscal 2010 was $123.67M, a 22.37% decline from fiscal 2009.
- PHARMACEUTICAL PRODUCT DEVELOPMENT INC net income (loss) attributable to parent for fiscal 2009 was $159.29M, a 15.05% decline from fiscal 2008.
- PHARMACEUTICAL PRODUCT DEVELOPMENT INC net income (loss) attributable to parent for fiscal 2008 was $187.52M.
| Period end | Net Income (Loss) Attributable to Parent 3 month | Net Income (Loss) Attributable to Parent 6 month | Net Income (Loss) Attributable to Parent 9 month | Net Income (Loss) Attributable to Parent 12 month |
|---|---|---|---|---|
| 2011-09-30 | $35.62M 10-Q · filed 2011-11-02 | $81.03M derived: sum of 2 quarters · filed 2011-11-02 | $118.40M 10-Q · filed 2011-11-02 | $165.88M derived: sum of 4 quarters · filed 2011-11-02 |
| 2011-06-30 | $45.41M 10-Q · filed 2011-08-04 | $82.78M 10-Q · filed 2011-08-04 | $130.26M derived: sum of 3 quarters · filed 2011-08-04 | $168.27M derived: sum of 4 quarters · filed 2011-11-02 |
| 2011-03-31 | $37.37M 10-Q · filed 2011-05-03 | $84.85M derived: sum of 2 quarters · filed 2011-05-03 | $122.85M derived: sum of 3 quarters · filed 2011-11-02 | $143.83M derived: sum of 4 quarters · filed 2011-11-02 |
| 2010-12-31 | $47.48M derived: 10-K 12 month − 10-Q 9 month · filed 2011-02-25 | $85.48M derived: sum of 2 quarters · filed 2011-11-02 | $106.46M derived: sum of 3 quarters · filed 2011-11-02 | $123.67M 10-K · filed 2011-02-25 |
| 2010-09-30 | $38.00M 10-Q · filed 2011-11-02 | $58.98M derived: sum of 2 quarters · filed 2011-11-02 | $76.18M 10-Q · filed 2011-11-02 | $95.18M derived: sum of 4 quarters · filed 2011-11-02 |
| 2010-06-30 | $20.98M 10-Q · filed 2011-08-04 | $38.18M 10-Q · filed 2011-08-04 | $57.17M derived: sum of 3 quarters · filed 2011-08-04 | $94.85M derived: sum of 4 quarters · filed 2011-08-04 |
| 2010-03-31 | $17.20M 10-Q · filed 2011-05-03 | $36.20M derived: sum of 2 quarters · filed 2011-05-03 | $73.87M derived: sum of 3 quarters · filed 2011-05-03 | $131.93M derived: sum of 4 quarters · filed 2011-05-03 |
| 2009-12-31 | $18.99M derived: 10-K 12 month − 10-Q 9 month · filed 2011-02-25 | $56.67M derived: sum of 2 quarters · filed 2011-02-25 | $114.73M derived: sum of 3 quarters · filed 2011-02-25 | $159.29M 10-K · filed 2011-02-25 |
| 2009-09-30 | $37.67M 10-Q · filed 2010-11-05 | $95.73M derived: sum of 2 quarters · filed 2010-11-05 | $140.30M 10-Q · filed 2010-11-05 | |
| 2009-06-30 | $58.06M 10-Q · filed 2010-08-06 | $102.63M 10-Q · filed 2010-08-06 | ||
| 2008-12-31 | $187.52M 10-K · filed 2011-02-25 |